Society Testimony

Testimony to FDA on Semaglutide

October 17, 2017

Endocrine Society Submitted Testimony to the Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee 

"The Society urges the FDA to give fair consideration of new options in combating this disease and to expedite the approval process for emerging therapies that, based on safety and efficacy data, have the potential to reduce complications and impact the progression of diabetes. "

arrow Read the Full Testimony

Last Updated:

Policy Communications

Take Action

Make Your Voice Heard

Take Action
We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

Journals

The Best of Endocrine Society Journals 2020

Explore a collection of top articles published in the Endocrine Society journals in 2020, selected on the basis of citations, downloads, and Altmetric score.

Explore a collection of top articles published in the Endocrine Society journals in 2020, selected on the basis of citations, downloads, and Altmetric score.

Back to top
Short on time?

We'll come to you...

Get updates on the latest breakthroughs, clinical practice guidelines, and career development opportunities, straight to your inbox

Then take the next step: Set up your free website account and get exclusive access to even more great tools & content!